AVIEW Lung Nodule CAD vs AVIEW
AI Verdict
Choose AVIEW Lung Nodule CAD if…
Choose AVIEW Lung Nodule CAD if your primary need is a highly specialized AI assistant for precise lung nodule detection, characterization, and longitudinal follow-up. This tool is ideal for radiologists seeking to efficiently screen for lung cancer, COPD, and coronary artery calcification simultaneously with robust nodule analysis and Lung-RADS reporting, focusing on the 'Big 3' screening.
View AVIEW Lung Nodule CAD →Choose AVIEW if…
Choose AVIEW if your institution requires a comprehensive, integrated AI platform that extends beyond basic nodule analysis to include advanced anatomical segmentation and workflow automation. This solution is best suited for practices looking to streamline their entire radiology workflow, incorporate detailed Interstitial Lung Disease (ILD) pattern analysis, and achieve deeper integration with existing PACS/RIS/CIS systems for a holistic diagnostic approach to lung and cardiac conditions.
View AVIEW →When choosing between AVIEW Lung Nodule CAD and AVIEW, physicians should consider their primary focus and desired breadth of AI-powered analysis. AVIEW Lung Nodule CAD is specifically designed to assist radiologists in the detection and analysis of pulmonary nodules on chest CT scans, offering features like nodule classification (solid, part-solid, non-solid), 3D size and volume quantification, and automatic report generation based on Lung-RADS classification. It also includes nodule matching and volume doubling time (VDT) calculation for follow-up comparisons.
The key practical difference lies in their scope. While AVIEW Lung Nodule CAD is a specialized tool for lung nodule management, the broader AVIEW platform offers a more comprehensive suite of AI-driven diagnostic solutions. AVIEW encompasses all the lung nodule detection and characterization features found in AVIEW Lung Nodule CAD, but extends its capabilities to include automated segmentation of lung lobes, airways, vessels, and coronary arteries, as well as Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture). Both tools provide simultaneous analysis for lung cancer, COPD, and coronary artery calcification, often referred to as the “Big 3” diseases.
Therefore, a physician whose primary need is robust, dedicated AI assistance for lung nodule detection, characterization, and follow-up, should consider AVIEW Lung Nodule CAD. For practices seeking an integrated diagnostic ecosystem that combines lung cancer screening with extensive analysis of pulmonary, cardiac, and airway pathologies, AVIEW would be the more suitable choice, streamlining workflows and enhancing diagnostic precision across multiple areas.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AVIEW Lung Nodule CAD | AVIEW |
|---|---|---|
| Pricing | Contact for pricing | Subscription; one-off payment |
| Deployment | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWTool B explicitly highlights 'Workflow automation and integration with PACS/RIS/CIS' and a 'plug-in-based architecture that integrates seamlessly with existing PACS and RIS systems', suggesting a more robust and streamlined integration into existing clinical environments. While Tool A mentions DICOM compliance and PACS linking, Tool B's description implies a more advanced and comprehensive workflow integration for enhanced user experience.
Clinical Value
AVIEWBoth tools offer strong clinical value for lung nodule detection, emphysema, and coronary artery calcification. However, Tool B extends its diagnostic scope with explicit features like 'Automated segmentation of lung lobes, airways, vessels, and coronary arteries' and 'Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture)', providing a broader range of clinical insights and more comprehensive diagnostic capabilities.
Pricing & Value
AVIEWTool B offers more transparency in its pricing model by explicitly stating 'subscription; one-off payment' and detailing that pricing is 'Based on: Number of installations, Number of users.' This provides potential customers with a clearer understanding of cost structures compared to Tool A's less detailed 'contact for pricing' information.
Enterprise Readiness
AVIEWBoth tools are HIPAA compliant, FDA cleared, and offer identical flexible deployment options. While Tool A received FDA clearance renewal with strengthened cybersecurity criteria, Tool B (the broader AVIEW platform) has demonstrated extensive real-world validation, processing over 2.5 million cases across 19 countries and integrating into major U.S. medical centers, indicating a proven track record of enterprise-scale deployment and stability.
Innovation
AVIEWWhile both leverage AI, Tool B demonstrates greater innovation with features like 'Automated segmentation of lung lobes, airways, vessels, and coronary arteries' and 'Interstitial Lung Disease (ILD) pattern analysis (AVIEW Lung Texture)'. Furthermore, the description of AVIEW 2.0 (aligning with Tool B) as a 'paradigm shift from task-specific tools to an integrated diagnostic ecosystem' suggests a more holistic and advanced AI architecture.
Support & Docs
TieAs both tools are products of Coreline Soft, the general company support and documentation resources would apply to both. The provided facts and web searches do not offer specific differentiating information regarding the quality, availability, or depth of support and documentation for one tool over the other.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AVIEW Lung Nodule CAD | AVIEW |
|---|---|---|
| Product Name | AVIEW Lung Nodule CAD | AVIEW |
| Tagline | Advancing Radiology with AI | AI-Driven Diagnostic Solutions for Medical Imaging |
| Lung Nodule Detection & Characterization | AI-based pulmonary nodule detection (3-20 mm) on CT scans; Nodule classification (solid, part-solid, non-solid); 3D nodule size and volume quantification | AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score) |
| Emphysema Analysis | Quantitative emphysema analysis (e.g., Low Attenuation Area - LAA, emphysema index); Simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3) | Emphysema quantification and low attenuation area (LAA) analysis |
| Coronary Artery Calcification (CAC) Scoring | Agatston, volume, mass scores; Simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3) | Agatston, volume, mass score, risk stratification |
| Reporting & Visualization | Automatic report generation based on Lung-RADS classification | 3D visualizations and comprehensive PDF reports |
| Follow-up & Nodule Matching | Nodule matching and volume doubling time (VDT) calculation for follow-up comparisons | Follow-up registration and nodule matching for serial CT scans |
Videos
Demos, reviews, and walkthroughs featuring AVIEW Lung Nodule CAD and AVIEW.